U.S. Water Utilities Stock News

NasdaqGS:MRVL
NasdaqGS:MRVLSemiconductor

Marvell (MRVL) Stock Looks Cheap On Cash Flow Yet Pricey On Earnings

Marvell Technology has delivered a very large 3 year gain, yet its valuation checks are split, with the Discounted Cash Flow (DCF) intrinsic value pointing to some upside while market based multiples lean expensive. That mix leaves you weighing a stock that has already run hard against indicators that do not all point in the same direction. Over the past 3 years, Marvell Technology has returned about 337.3%, which sets a high bar for any further upside case. The planned acquisition of...
NYSE:EAT
NYSE:EATHospitality

Is Brinker International (EAT) Below Fair Value After Its Latest Earnings Report?

Brinker International (EAT) moved into focus after reporting fourth quarter fiscal 2026 earnings that matched expectations, with revenue ahead of forecasts. Chili's drove results, while Maggiano's contended with softer traffic and restaurant closures. Brinker International’s share price has pulled back recently, with a 7-day share price return down 7.7% and a 30-day return down 13.6%. However, the 90-day share price return of 33.4%, year-to-date gain of 40.2%, and a three-year total...
NYSE:GD
NYSE:GDAerospace & Defense

General Dynamics (GD) Stock Could Be 23% Below Fair Value On Cash Flow

General Dynamics stock has more than doubled over the past five years, yet both an intrinsic value estimate and earnings multiples still lean toward the shares trading below a cautious appraisal of the business. That mix of strong long term returns and signals of potential undervaluation puts the current US$355.90 price in focus for anyone trying to weigh upside against execution and cash flow risks. The share price has returned 102.6% over five years, which puts General Dynamics in the...
NYSE:EQT
NYSE:EQTOil and Gas

EQT (EQT) Wins Lithuania LNG Supply Deal Through 2036

EQT (NYSE:EQT) said a subsidiary won a long term LNG supply tender with Lithuanian energy group UAB Ignitis starting in 2027. The agreement covers LNG cargo deliveries into Lithuania from 2027 through 2036 under a competitive international procurement process. The supply structure provides exposure to both US and European gas price benchmarks for the contracted LNG volumes. This new EQT LNG contract with UAB Ignitis from 2027 to 2036 needs weighing against the rest of our EQT view. Check out...
NasdaqGS:META
NasdaqGS:METAInteractive Media and Services

Why Is Meta Platforms (META) Buying AI Messaging Tools And Eyeing Argentina?

Meta Platforms (NasdaqGS:META) has agreed to acquire Swedish AI startup Stilla.ai to expand automated business messaging across its apps. The Stilla.ai deal is aimed at boosting AI driven customer support tools on WhatsApp, Messenger and Instagram for commercial users. Meta and other large tech groups are assessing Patagonia in Argentina for new data centers as US community opposition to such projects grows. The Stilla.ai acquisition and Argentina data center review are only part of the...
NasdaqGS:ASO
NasdaqGS:ASOSpecialty Retail

Academy Sports And Outdoors (ASO) Brings Premium Running Shoes To Southern Stores Online

Academy Sports + Outdoors (NasdaqGS:ASO) has begun offering Hoka performance running shoes in select Southern stores and on its e-commerce platform. The rollout brings a premium running brand into Academy's assortment, widening choice for shoppers who want higher end athletic footwear. The move aligns with Academy Sports + Outdoors' focus on branded merchandise alongside its value offering as it refreshes key categories. The Hoka launch is important, but investors should weigh it alongside...
NasdaqGS:EXEL
NasdaqGS:EXELBiotechs

Exelixis (EXEL) Gets Longer FDA Review As Cancer Pipeline Milestone Advances

Exelixis (NasdaqGS:EXEL) reported that the FDA extended its review of the zanzalintinib NDA in metastatic colorectal cancer after new safety and efficacy data submissions. The regulator added time to the review clock following Exelixis' update to the application, which included additional clinical information. Exelixis reached a collaboration milestone with Adagene in their antibody drug conjugate program, triggering a contractual milestone payment. The FDA's extended zanzalintinib review...
NasdaqGS:FLYW
NasdaqGS:FLYWDiversified Financial

Flywire (FLYW) Could Be 12% Undervalued Following Davidson Hospitality Expansion

Why Flywire’s New Hospitality Partnership Matters Flywire (FLYW) has expanded its relationship with Davidson Hospitality Group, rolling out its payment and e-signature tools across more properties after Davidson reported meaningful processing fee savings and faster guest deposit and contract workflows. Recent trading shows Flywire’s 90-day share price return of 21.48% and year-to-date gain of 28.56% have been strong, while the 1-year total shareholder return of 33.86% contrasts with a 3-year...
NYSE:DHR
NYSE:DHRLife Sciences

Danaher (DHR) Precision Medicine Story Keeps Fair Value In Focus

Recent commentary on Danaher (DHR) has focused on the stock’s limited upside compared with the S&P 500, tying that underperformance to concerns around organic revenue trends, margins, and earnings per share. Over the past year Danaher has delivered a 6.1% total shareholder return, even though the share price is down 13.1% year to date and recently eased from its 90 day gain of 11.1%. This points to fading short term momentum despite a more resilient longer term picture when dividends are...
NasdaqGS:CHRW
NasdaqGS:CHRWLogistics

Is C.H. Robinson Worldwide (CHRW) Too Expensive After The $604M Verdict?

C.H. Robinson Worldwide has delivered a strong 5 year run for shareholders, yet current valuation checks suggest the stock now trades at a premium to what its intrinsic value estimate implies. The share price return of 95.7% over 5 years points to a business that investors have rewarded heavily. Management’s handling of the US$604m legal verdict and potential insurance cost pass through can influence how investors think about future cash flows and risk. The company screens as overvalued on...
NasdaqGS:PAYX
NasdaqGS:PAYXProfessional Services

Paychex (PAYX) Faces A Paycor Test As Fair Value Looks Close

Paychex (PAYX) has drawn investor attention after recent price moves and mixed short term returns. The payroll and HR services stock last closed at $115.80, with performance varying sharply between the past month and the past 3 months. Recent trading suggests momentum for Paychex is softening in the short run, with the share price down 4.9% over the past week and 3.8% over the past month. This comes even though the 3 month share price return of 15.1% and 3 year total shareholder return of...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

BridgeBio Pharma (BBIO) Highlights PROPEL 3 Data, Is The Valuation Upside Still Open?

BridgeBio Pharma (BBIO) returned to focus after fresh PROPEL 3 data on oral infigratinib in achondroplasia, with management highlighting 52 week trends in sleep apnea, ear infections, growth and body proportionality. BridgeBio Pharma’s latest PROPEL 3 update lands after a choppy stretch in the market, with the share price at US$72.44 and a 30 day share price return down 13.6%, even as the 1 year total shareholder return is up 41.46% and the 3 year total shareholder return is up 148.68%. This...
NYSE:LMND
NYSE:LMNDInsurance

What’s Going On With Lemonade (LMND)?

Lemonade (LMND) just broadened its footprint, rolling out renters insurance in Kentucky and Kansas, alongside Lemonade Car and an Autonomous Car pricing program for Missouri Tesla drivers. Lemonade is expanding into new states at a time when momentum in the share price has cooled, with the stock down 7.5% over the past week and 35% year to date on a share price basis, even as the three-year total shareholder return remains very large. Scan beyond Lemonade and see how other insurers are being...
NYSE:ST
NYSE:STElectrical

Should New EV Components Require Action From Sensata Stock Investors?

Sensata Technologies recently introduced its OmniNode high voltage power distribution platform for commercial vehicles and its R290 Pressure + Temperature Sensor for electrified thermal systems, both aimed at simplifying engineering, meeting safety rules and supporting OEM adoption of new architectures and refrigerants. These launches push Sensata Technologies further into system level solutions, where combining multiple functions in one module can affect content per vehicle, customer...
NYSE:U
NYSE:USoftware

Unity Software (U) Climbed, But What Is Drawing Attention Now?

Unity Software (U) is back in focus as the next earnings report approaches and Wall Street weighs projected jumps in earnings per share and revenue against weaker long term growth, softer billings and thinning margins. Recent trading has been choppy. Unity Software’s share price has climbed 61.4% over the past 90 days and the 1 year total shareholder return is 0.9%. However, the 5 year total shareholder return is still down 67.8%, which signals that momentum has picked up in the short term...
NYSE:MOH
NYSE:MOHHealthcare

Molina Healthcare (MOH) Stock Looks Below Fair Value Despite Weaker Sales

Molina Healthcare comes into focus as a stock with solid gains over the past year but a sharp decline of about 38% over three years, while its valuation checks still flag it as cheap on the broader metrics. Recent revenue pressure and customer losses have unsettled sentiment, yet the current pricing screens as undervalued on core multiples. The share price has fallen roughly 38% over three years, which suggests longer term holders have absorbed a heavy drawdown that is not fully reflected in...
NasdaqGS:DNLI
NasdaqGS:DNLIBiotechs

Denali Therapeutics (DNLI) Stock Looks Stretched On Fair Value Yet Reasonable On Book Value

Denali Therapeutics has delivered a strong 1 year rebound for shareholders, yet multiple valuation checks suggest the current share price sits above where an intrinsic value estimate and market based comparisons would place it. The stock therefore looks priced for meaningful execution on its drug pipeline even after a difficult 5 year stretch. Over 5 years, Denali Therapeutics shareholders have seen the investment fall about 60%, which hints that earlier optimism has not yet translated into...
NasdaqGS:CG
NasdaqGS:CGCapital Markets

Is Carlyle Group (CG) Cheap Following Exiger's AI Platform Launch?

Carlyle Group (CG) is back in focus after portfolio company Exiger rolled out its AI native 1Exiger platform, following a US$1.2b investment round that involved Carlyle and other backers. Despite Exiger’s AI push grabbing headlines, Carlyle Group’s recent share price performance has been weak. The stock is down 12.29% over 30 days and 30.43% year to date, while a 3-year total shareholder return of 38.05% shows a more constructive longer-term record. Scan other private markets and AI exposed...
NYSE:CLX
NYSE:CLXHousehold Products

Clorox (CLX) Slides Into The Valuation Spotlight, Is The Stock 14% Undervalued?

Clorox (CLX) has come under pressure recently, with the share price down 17% over the past month and 9% in the past 3 months. This has put the consumer staples group back under the microscope for investors. Zooming out, Clorox’s 1-year total shareholder return is down 25.63%, and the 3-year and 5-year total shareholder returns are also lower. This suggests that recent weakness in the share price is part of a longer period of fading momentum around the stock. Compare Clorox’s recent slide with...
NasdaqGS:FSLY
NasdaqGS:FSLYIT

Fastly (FSLY) Stock Could Be Above Fair Value On Growth Hopes

Fastly stock has almost tripled over the past year, yet the broader valuation checks suggest the current share price leans expensive rather than offering clear value. The 199.6% return over the past 12 months highlights how quickly expectations around Fastly have shifted and raises the bar for what needs to go right next. Expectations for continued adoption of Fastly's edge computing and content delivery services can support a higher valuation. However, any setback in turning that usage into...
NYSE:APAM
NYSE:APAMCapital Markets

Is Artisan Partners Asset Management (APAM) Stock A Bargain Or Fully Priced?

Artisan Partners Asset Management stock has fallen over recent months, yet several valuation checks suggest the shares may be pricing in more caution than the business fundamentals imply. After a three year gain of 30.7%, the recent pullback leaves investors weighing a cheaper entry point against the usual uncertainties around future fee income and fund flows. Over the past 3 years, Artisan Partners Asset Management has returned 30.7%, which points to meaningfully positive longer term...
NYSE:LUV
NYSE:LUVAirlines

Southwest Airlines (LUV) Could Be 24% Undervalued As Seating Changes Come Into View

Southwest Airlines (LUV) has drawn investor attention after recent share price weakness, with the stock down about 13% over the past month and roughly 14% over the past 3 months. The recent 12.8% 1 month and 13.7% 3 month share price declines suggest momentum for Southwest Airlines is fading in the short term, even though the 1 year total shareholder return of 26.2% and 3 year total shareholder return of 40.9% still point to a stronger longer run record. Scan for other airline and travel...
NYSE:FBIN
NYSE:FBINBuilding

Fortune Brands (FBIN) Appoints Peter G. Clifford As CFO And Executive Vice President

Fortune Brands Innovations (NYSE:FBIN) appointed Peter G. Clifford as Chief Financial Officer and Executive Vice President, effective September 21, 2026. Clifford brings more than 30 years of finance and operational leadership across building products and healthcare businesses. His background includes experience in finance transformation, global operations and M&A activity at publicly traded companies. The appointment of Peter G. Clifford as CFO and Executive Vice President is important...
NasdaqGS:TXG
NasdaqGS:TXGLife Sciences

10x Genomics (TXG) Stock Looks Expensive Despite Fresh AI Pathology Optimism

10x Genomics has delivered a very strong 1 year gain while the broader valuation checks still flag the stock as expensive rather than a clear bargain. The share price return over the past 12 months is 442.6%, which puts 10x Genomics among the more extreme recent movers in the market and raises the bar for what needs to go right next. The newly announced collaboration with Lunit on AI enabled pathology analysis can support optimism around long term demand, while execution risk in scaling the...